Merrimack Pharma (Nasdaq: MACK) announced additional clinical and biomarker data from a Phase 2 study in ER/PR-positive, HER2-negative metastatic breast ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE